Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 88 peer-reviewed journal articles Updated
Nephrology

Lupus Nephritis: A Patient Guide

At a Glance

Lupus nephritis is kidney inflammation from systemic lupus. A kidney biopsy shows the disease class and how much active inflammation or permanent scarring is present, guiding combination treatment, steroid tapering, and long-term monitoring to protect kidney function.

Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE) that occurs when the immune system mistakenly attacks the kidneys. In a healthy body, the immune system protects against infection, but in lupus, it produces autoantibodies that target the body’s own tissues. When these antibodies and the proteins they latch onto—known as immune complexes—travel through the bloodstream and become trapped in the kidney’s delicate filters, they trigger intense inflammation and damage [1][2]. Because the kidneys are responsible for filtering waste and balancing fluids, this inflammation can interfere with vital bodily functions and, if left untreated, may lead to permanent scarring of the organ [3][4].

How to Use This Guide: This guide is designed to help you understand your condition and partner with your medical team. It does not replace individualized medical advice. Never start, stop, or taper medications without your doctor’s guidance, and always seek local emergency services if you experience life-threatening symptoms.

To understand the exact nature of the injury, doctors rely on a kidney biopsy, which remains the gold standard for diagnosis and staging. A biopsy allows pathologists to categorize the disease into one of six classes (Class I through VI), ranging from mild changes to severe, widespread inflammation or advanced scarring [5]. This classification is further refined by measuring an activity index, which tracks current, reversible inflammation, and a chronicity index, which identifies permanent damage [6]. This detailed map of the kidney tissue is essential because blood and urine tests alone cannot always distinguish between an active flare that needs intensive treatment and older damage that requires a more protective, long-term approach [7].

Modern treatment strategies have shifted toward a more proactive, “upfront” approach to prevent kidney failure. For the more aggressive forms of the disease, guidelines now increasingly recommend combination therapy, where multiple medications—such as mycophenolate or cyclophosphamide alongside newer biologic or targeted drugs—are started early to shut down inflammation quickly [8][9]. While steroids remain a powerful tool for controlling acute flares, the current standard of care emphasizes a rapid tapering of these medications to the lowest possible dose to minimize long-term side effects [10][11]. This intensive initial phase is followed by a maintenance period that usually lasts several years to keep the disease in check and prevent future relapses [12][13].

Beyond immunosuppressive medications, the long-term management of lupus nephritis focuses on shielding the kidneys from further stress. This includes strict blood pressure control and the use of medications that reduce the physical pressure within the kidney’s filtration units [14][15]. Regular monitoring of urine protein levels and kidney function is a lifelong commitment for patients, as it allows the medical team to catch early signs of a flare before significant damage occurs [16]. With today’s advanced treatments and a focus on early intervention, many people with lupus nephritis can achieve stable kidney function and maintain a high quality of life, though outcomes vary based on your specific biopsy class, kidney function, and response to therapy [17][18].

In this guide

5 chapters

01

Understanding Lupus Nephritis: Why the Kidneys are Affected

Learn why lupus nephritis affects the kidneys, how immune complexes cause injury, what biopsy findings mean, and how activity and scarring guide your care.

02

Lupus Nephritis: Recognizing Symptoms and Emergency Signs

Learn to recognize lupus nephritis flare symptoms, track urine and blood pressure changes, and know when infection or breathing problems need emergency care.

03

Diagnosing Lupus Nephritis: Decoding Your Kidney Biopsy

Learn how to read a lupus nephritis kidney biopsy report, including ISN/RPS classes, activity and chronicity scores, immune staining, and other key findings.

04

Standard Treatments: Managing and Protecting Your Kidneys

Learn how lupus nephritis treatment works, including steroids, mycophenolate, triple therapy, maintenance medicines, kidney monitoring, and treatment goals.

05

Life with Lupus Nephritis: Protecting Your Kidneys Long-Term

Learn how lupus nephritis care protects kidney function with blood pressure control, lab tests, pregnancy planning, healthy habits, and maintenance treatment.

Common questions in this guide

What is lupus nephritis and why can it damage the kidneys?
Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus, an autoimmune disease. Immune proteins can become trapped in the kidneys' filters, causing inflammation that interferes with waste and fluid balance and may lead to scarring or kidney failure if untreated.
How is lupus nephritis diagnosed and classified?
A kidney biopsy is the main test used to confirm and stage lupus nephritis. It lets pathologists place the disease into one of six classes and assess how much active inflammation and permanent scarring are present; blood and urine tests alone may not show the difference.
What do the activity and chronicity scores mean?
The activity score reflects current inflammation that may improve with treatment. The chronicity score reflects lasting scarring or other permanent damage, so together they help clinicians decide how intensive treatment should be and how much long-term kidney protection is needed.
What medications are used to treat lupus nephritis?
Treatment may combine medicines such as mycophenolate or cyclophosphamide with belimumab or voclosporin for more aggressive disease. Steroids can control flares, but clinicians generally taper them toward the lowest effective dose, followed by maintenance treatment that may continue for several years.
How will my doctor monitor lupus nephritis?
Your care team will regularly check urine protein, kidney function, blood pressure, and often blood tests to look for treatment effects or an early flare. Report new swelling or changes in urine, and do not stop or change medication without medical guidance.
Can lupus nephritis be controlled over the long term?
Many people can achieve stable kidney function and maintain a good quality of life with early treatment and ongoing monitoring. Outlook varies with biopsy class, current kidney function, and how well the disease responds to therapy.
What can I do to protect my kidneys with lupus nephritis?
Take medications consistently as prescribed, keep follow-up appointments, and work with your care team on personalized blood pressure and urine-protein targets. Kidney-protective medicines may reduce pressure in the kidney filters, and regular monitoring can detect a flare before major damage occurs.

Get notified when new evidence is published on Lupus nephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis.

    Tsai CY, Li KJ, Shen CY, et al.

    International journal of molecular sciences 2023; (24(12)) doi:10.3390/ijms241210066.

    PMID: 37373215
  2. 2

    Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue.

    Kwant LE, Vegting Y, Tsang-A-Sjoe MWP, et al.

    Autoimmunity reviews 2022; (21(12)):103211 doi:10.1016/j.autrev.2022.103211.

    PMID: 36252930
  3. 3

    Decoding Lupus Diagnosis, Pathogenesis and Therapy: From Systemic Autoimmunity to Renal Damage.

    Netti GS, Troise D, Infante B, et al.

    Diagnostics (Basel, Switzerland) 2026; (16(14)) doi:10.3390/diagnostics16142170.

    PMID: 42510034
  4. 4

    Beyond glomeruli in lupus nephritis: Impact of tubulointerstitial inflammation and interstitial fibrosis/tubular atrophy on renal function decline - A systematic review and meta-analysis.

    Donato KO, Donato AO, Gonçalves LF, et al.

    Lupus 2026; (35(7)):709-721 doi:10.1177/09612033261437467.

    PMID: 41860784
  5. 5

    Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.

    Bajema IM, Wilhelmus S, Alpers CE, et al.

    Kidney international 2018; (93(4)):789-796 doi:10.1016/j.kint.2017.11.023.

    PMID: 29459092
  6. 6

    Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance.

    Choi SE, Fogo AB, Lim BJ

    Kidney research and clinical practice 2023; (42(2)):166-173 doi:10.23876/j.krcp.22.083.

    PMID: 37037479
  7. 7

    Development of an instrument to predict proliferative histological class in lupus nephritis based on clinical and laboratory data.

    Silaide de Araújo Júnior A, Sato EI, Silva de Souza AW, et al.

    Lupus 2023; (32(2)):216-224 doi:10.1177/09612033221143933.

    PMID: 36461171
  8. 8

    New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies.

    Ibrahim M, He E, Tran D, et al.

    Best practice & research. Clinical rheumatology 2026; (40(3)):102153 doi:10.1016/j.berh.2026.102153.

    PMID: 42097966
  9. 9

    Current treatment of lupus nephritis: an overview of the new guidelines.

    Sales GTM, Macedo NJ, Reis Neto ETD, Kirsztajn GM

    Jornal brasileiro de nefrologia 2025; (47(4)):e20250092 doi:10.1590/2175-8239-JBN-2025-0092en.

    PMID: 41082628
  10. 10

    EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

    Fanouriakis A, Kostopoulou M, Andersen J, et al.

    Annals of the rheumatic diseases 2024; (83(1)):15-29 doi:10.1136/ard-2023-224762.

    PMID: 37827694
  11. 11

    Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.

    Xipell M, Iraola M, Mirioglu S, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag106.

    PMID: 42101868
  12. 12

    2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

    Fanouriakis A, Kostopoulou M, Cheema K, et al.

    Annals of the rheumatic diseases 2020; (79(6)):713-723 doi:10.1136/annrheumdis-2020-216924.

    PMID: 32220834
  13. 13

    The 2024 APLAR Consensus on the Management of Lupus Nephritis.

    Mok CC, So H, Hamijoyo L, et al.

    International journal of rheumatic diseases 2025; (28(1)):e70021 doi:10.1111/1756-185X.70021.

    PMID: 39744836
  14. 14

    Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.

    Castro M, Ugolini-Lopes M, Borba EF, et al.

    Lupus 2018; (27(14)):2215-2219 doi:10.1177/0961203318809883.

    PMID: 30394834
  15. 15

    Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?

    Tselios K, Gladman DD, Su J, Urowitz MB

    The Journal of rheumatology 2020; (47(9)):1366-1373 doi:10.3899/jrheum.191064.

    PMID: 32238519
  16. 16

    II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.

    Reis-Neto ETD, Seguro LPC, Sato EI, et al.

    Advances in rheumatology (London, England) 2024; (64(1)):48 doi:10.1186/s42358-024-00386-8.

    PMID: 38890752
  17. 17

    Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis.

    Zhang S, Magder L, Goldman D, et al.

    Arthritis care & research 2026; doi:10.1002/acr.80070.

    PMID: 42047336
  18. 18

    Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.

    Mok CC, Ho LY, Ying SKY, et al.

    Annals of the rheumatic diseases 2020; (79(8)):1070-1076 doi:10.1136/annrheumdis-2020-217178.

    PMID: 32448782

This guide is for informational purposes only and does not constitute medical advice. Your nephrologist and rheumatologist should interpret your biopsy and guide medication changes for your individual situation.